Newsroom
Basket Trials Have FDA Support, But Will They Deliver?
Following the introduction of adaptive clinical trials, cancer researchers are now working on another revolutionary model, and they have the FDA's support in this effort. Named basket studies because they group different cancers together based on the driver mutation rather than the tumor of origin, these trials do not use the standard treatment as a control group, but look for a "Yes" or "No" response.
Sanofi's Long-Acting, Once-Daily Basal Insulin Approved
Significant results from an international phase 3 study, EDITION, resulted in the approval of Toujeo in treating patients with type 1 as well as type 2 diabetes.
Medical ID Theft on the Rise
Medical identity theft jumped 22% last year as more US health data becomes electronic and easier for cyber criminals to steal from doctors’ offices, hospitals and insurers.
CMS Seeks to Update Payments, Policies for Medicare Health and Drug Plans
CMS has released proposed changes for the Medicare Advantage and Part D Prescription Drug Programs that help build a better, smarter healthcare system and move the Medicare program toward paying providers based on quality of care.
Fred Hutch Receives Multimillion Dollar Cancer Research Grant from PCORI
Project to research better way to treat neutropenia is 1 of 5 to get latest funding from Patient-Centered Outcomes Research Institute.
CMS Extends Medicare Meaningful Use Deadline
Eligible healthcare professionals participating in the Medicare Electronic Health Record (EHR) Incentive Program 2014 reporting year will have additional time to attest to meaningful use, according to an announcement from CMS.
Onclive Welcomes Medical University of South Carolina’s Hollings Cancer Center to Strategic Alliance Partnership Program
OncLive today welcomes the Medical University of South Carolina's Hollings Cancer Center as a partner in promoting the latest advances in cancer research, treatment and care through OncLive's Strategic Alliance Partnership program.
Cancer Prevention Could Begin With HIV-Infected Populations, Study Shows
The study, published in the current issue of the Journal of the National Cancer Institute determined that the total cancer burden was highest among people in the 50-59 years age bracket, men who have sex with men, those living 5 or more years with AIDS, and non-Hispanic blacks. But the largest excess burden was among people 15-29 years old.
NICE Rejects Provenge, Says Treatment is Not Cost-Effective
The governing body for public health in the UK, National Institute for Health and Care Excellence, has refused to fund Provenge citing a high-price for the benefit the tretament provides. This may not be the best news for Valeant Pharmaceuticals which recently bought the regimen from the bankrupt Dendreon Corp.
Shared Decision-Making in Cancer Has Several Variables
A study published in the journal Cancer provides insights that may help physicians understand patients' preferences regarding their care, which may be crucial for optimizing patient participation in treatment decisions.
Patient Satisfaction Not Influenced by Fancy Hospital Renovations
For decades, hospital executives across the country have justified expensive renovation and expansion projects by saying they will lead to better patient reviews and recommendations.
Stark Uninsured Rate Differences Across the Country
The difference in uninsured rates in states that have embraced the Affordable Care Act and those that have not became even starker in 2014, according to new results from the Gallup-Healthways Well-Being Index.
Study Results Could Improve Quality of Life in Pediatric ALL
The study, conducted in 2 separate patient cohorts at St. Jude Children's Hospital and the Children's Oncology Group and published in the The Journal of the American Medical Association, found that children with gene variants in the CEP72 gene were more sensitive to vincristine-induced peripheral neuropathy.
Study Warns Against Use of VEGF Inhibitors in Advanced Kidney Cancer
Interim analysis of a clinical trial evaluating adjuvant sorafenib, sunitinib or placebo in patients with advanced renal cell carcinoma found the recurrence rates and the disease-free survival were similar between all three treatment regimens.
UCLA Health System President Stepping Down for Geisinger Position
The president of the UCLA Health System, which is still contending with the outbreak of a superbug that infected 7 patients and killed 2, is stepping down from his position for a new appointment as president and chief executive officer of Geisinger Health System.
First HDAC Inhibitor, Developed by Novartis, Approved for Multiple Myeloma
Study results showed participants receiving Farydak with bortezomib and dexamethasone saw a progression-free survival for about 10.6 months,compared to 5.8 months in participants treated with bortezomib and dexamethasone alone.
Coalition of Leading Cancer Centers Aims to Improve Personalized Treatment
“The growth of ORIEN coincides with President Obama’s announcement and the recognition that molecularly targeted medicine holds tremendous promise for all disease, particularly cancer,” said Michael Caligiuri, MD, director of The Ohio State University Comprehensive Cancer Center and CEO of the James Cancer Hospital and Solove Research Institute.
BMS Deals Set to Boost Company's Oncology Pipeline
The deals, with Flexus and Rigel, will add another molecule to the company's immunotherapy pipeline and also provide access to a TGF-beta receptor inhibitor to be used in combination with Yervoy and Opdivo.
EHR Use Sharply Increased in Emergency Departments
With the availability of government incentives, electronic health record use among hospital emergency departments and outpatient departments increased sharply from 2006 to 2011, according to a new analysis from the National Center on Health Statistics.
Physicians May Be Underestimating Patients’ Nonadherence
While physicians recognize medication adherence is an extremely important factor in clinical outcomes for patients with chronic conditions, respondents in a new survey seemed to overestimate the medication adherence and persistence of their own patients.
Taiho's NDA for mCRC Under FDA Review
The TAS-102 RECOURSE trial met the primary efficacy endpoint of statistically significant improvement in overall survival versus placebo, and the results of the trial form the basis of the NDA.
Medicare Part D Saved 27,000 People With CVD Treatment Access
The Medicare prescription-drug benefit introduced in 2006 saved an estimated 19,000 to 27,000 lives in its first year by expanding access to medications that treat cardiovascular killers like strokes and heart disease.
HHS Sends Wrong Tax Information to 800,000 HealthCare.gov Users
The federal government sent incorrect tax information to about 800,000 people who purchased health insurance last year through HealthCare.gov and asked them to delay filing their returns, Obama administration officials said Friday.
Should CMS Rethink Analysis of Patient Satisfaction Surveys?
According to a healthcare consultant, hospitals that handle high patient volume tend to receive lower patient satisfaction scores than the smaller, specialty hospitals. The discrepancy in the patient demographic and the kind of procedures being conducted need to be considered when evaluating hospitals, experts think.
Expert Analysis on Managing mCRC
At the 26th International Congress on Anti-Cancer Treatment in Paris, France, earlier this month, oncologists deliberated on the current understanding of metastatic colorectal cancer and the available treatment options. Recent work has shown that there are 4 or 5 different subtypes of the disease, which may call for personalized therapeutic strategies.